NEW YORK, NY -- (Marketwired) -- 04/03/13 -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Adocia (EURONEXT PARIS: ADOC), a biotechnology company focused on the development of best-in-class medicines from already approved therapeutic proteins using the BioChaperone technology. Adocia's lead product candidate, BioChaperone PDGF-BB, is a potential best-in-class drug for wound healing. It is slated to begin pivotal Phase III studies in 2013 in India for patients with diabetic foot ulcers. Adocia also has Phase II clinical programs for potential best-in-class fast-acting human insulin and insulin combinations. Moreover, Adocia has a partnership with Eli Lilly to develop an ultra-fast-acting Humalog, Lilly's leading insulin compound. This product is in Phase I.
"Adocia's BioChaperone technology has the potential to improve the efficacy, safety, and cost of a variety of protein therapeutics, including growth factors, insulin, and monoclonal antibodies," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The Company's innovative products could revolutionize the insulin delivery market, with a fast-acting and combination insulin products in development. The partnership with Eli Lilly, worth up to $165 million, provides important validation of the approach."
In February 2012, Adocia announced positive results from a Phase IIa clinical trial evaluating the safety and efficacy of HinsBet, a fast-acting human insulin for the treatment of type 1 diabetes. An optimized formulation is set to enter an additional Phase IIa trial, which is scheduled to launch in the second half of 2013. Adocia is also in pre-clinical development of a fast and slow-acting insulin combination therapy, and the data from pre-clinical models showed promise.
In addition to innovative insulin therapies, Adocia is developing a BioChaperone application aimed at the wound healing market. The planned Phase III program for BioChaperone PDGF-BB follows positive Phase II data. The Phase II trial enrolled 192 patients and revealed that BioChaperone PDGF-BB is non-inferior to the standard of care Regranex Gel. The non-inferior efficacy was achieved with one-third the total dose of PDGF, and with one application every two days versus every day for Regranex. The spray application method of PDGF-BB, when compared to Regranex Gel, results in lower cost, higher patient compliance, and improved safety. Given a more convenient dosing schedule, improved stability profile, and advantages over other growth factor treatments for wound healing, Adocia's improved, cost-effective treatment may provide a lucrative opportunity in both developed and emerging markets.
In a 35 page Initiation Report by LifeSci Advisors, we discuss the scientific basis of Adocia's BioChaperone technology, provide insight into clinical trial development, and give an in-depth overview of the diabetes and ulcer disease markets. This includes disease background and market information, current treatment options, current products and those in clinical development, and BioChaperone's strategy to compete in these markets. Also included are analyses of the competitive landscape of current therapies, Adocia's current financial position, and a discussion of their strategic partnership with Eli Lilly.
Most Popular Stories
- Boehner Lashes Out Against Ted Cruz, Far Right
- TFA Recruiting DACA Recipients
- Hawaii Official Who Release Obama Certificate Only Victim of Plane Crash
- Holiday Shopping Off to a Slow Start This Season
- Ford Plans New Cars, Jobs in 2014
- Gold, Silver Slide on Prospects of Fed Exit
- 'Rape Insurance' Bill Passes in Michigan
- Ted Cruz Coloring Book Selling Briskly
- Kim Jong Un's Uncle Executed
- Grizzly Bears Could Be Taken Off Endangered List